Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...

According to the National Cancer Institute's website, KRAS is a gene that makes a protein involved in cell signaling pathways that regulate cell growth, maturation and death. The normal form of the ...

The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.